Virtual Organization Focused on Clinical Milestones

Bellicum has operated since inception as a fully virtual company. However, we are currently expanding the team in preparation for multi-center clinical trials of our two lead products.

• Thomas J. Farrell - Chief Executive Officer
  Thomas Farrell joined Bellicum in February 2006. He has a twelve year track record as a serial life science entrepreneur. Prior to joining Bellicum, he was founding President & CEO of San Diego-based Cylene Pharmaceuticals, a venture-backed company developing a novel class of small molecules as anti-cancer therapy, targeting secondary DNA structures and associated kinases. He received his M.B.A. at Stanford Graduate School of Business, where he was an Arjay Miller Scholar.
• Kevin M. Slawin, MD - Co-Founder, President & Chief Medical Officer
  Kevin Slawin is Director, Vanguard Urologic Institute and the Texas Prostate Center; Professor, Center for Clinical and Translational Sciences, UTHSC-Houston; Clinical Professor of Urology, Baylor College of Medicine; and Director of Urology, Memorial Hermann Hospital – TMC. He is a pioneer in the field of robotic surgery, co-inventor of the [-2]proPSA prostate cancer screening test, and a thought leader in the diagnosis and treatment of prostate cancer. As CMO, Dr Slawin has strategic responsibility for the company’s clinical activities.
• David M. Spencer, Ph.D. - Co-Founder and Chief Scientific Officer
  David Spencer, Professor and Vice Chairman of Pathology & Immunology, Baylor College of Medicine, is the original inventor of CID technology. Drs. Spencer and Slawin are co-inventors of DeCIDe™ and CaspaCIDe™, the two CID applications that have since entered the clinic. Dr. Spencer’s academic research program remains focused on CID, and he directs Bellicum’s preclinical research activities.

To complement the founding management team, we use consultants in the areas of manufacturing, quality, and regulatory affairs, and we use a full service CRO for clinical trials management.